The combination of MK-0752 with gemcitabine for the treatment of metastatic pancreatic cancer had a favorable pharmacokinetic and safety profile, and in a preliminary setting of a phase I trial, 13 of 19 patients had SD and one had a PR (NCT01098344); however, the matched pre/post-treatment tumor samples were characterized by a surprisingly low basal expression of HES1, contrasting with effective inhibition of Notch signaling in the hair follicles of these patients [397]. Here, HES1 is linked to neoplasm.